CA2296558A1 - The use of angiostatic steroids in photodynamic therapy of ocular neovascularization - Google Patents

The use of angiostatic steroids in photodynamic therapy of ocular neovascularization Download PDF

Info

Publication number
CA2296558A1
CA2296558A1 CA002296558A CA2296558A CA2296558A1 CA 2296558 A1 CA2296558 A1 CA 2296558A1 CA 002296558 A CA002296558 A CA 002296558A CA 2296558 A CA2296558 A CA 2296558A CA 2296558 A1 CA2296558 A1 CA 2296558A1
Authority
CA
Canada
Prior art keywords
neovascularization
angiostatic
steroids
pregnadien
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002296558A
Other languages
French (fr)
Inventor
Abbot F. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2296558A1 publication Critical patent/CA2296558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Abstract

Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steroid are disclosed.

Description

s THE USE OF ANGIOSTATIC STEROIDS IN PHOTODYNAMIC THERAPY
~o Field of the Invention:
This invention relates to the use of angiostatic steroids in photodynamic therapy (PDT).
Description of the Related Art:
~s Steroids functioning to inhibit angiogenesis in the presence of heparin or specific heparin fragments are disclosed in Cram, et al., A New Class of Steroids Inhibits Angiogenesis In The Presence of Heparin or Heparin Fragment, Science, 230:375-378, December 20, 1985.
The authors refer to such steroids as "angiostatic" steroids. Included in the new class of steroids found to be angiostatic are cortisol, cortexolone, and several dihydro and tetrahydro derivatives.
zo In a follow up study directed to testing a hypothesis as to the mechanism by which the steroids inhibit angiogenesis, it was shown that heparin/angiostatic steroid compositions caused dissolution of the basement membrane scaffolding to which anchorage dependent endothelia are attached resulting in capillary involution; see, Ingber, et al. A Possible Mechanism for Inhibition of Angiogenesis by ArZgiostatic Steroids: Induction of Capillay~ Basement Membrane 2s dissolution, Endocrinology 119:768-775, 1986.
A group of tetrahydrosteroids useful in inhibiting angiogenesis is disclosed in U.S. Patent No. 4,975,537, issued to Aristoff, et al. The compounds are disclosed for use in treating head trauma, spinal trauma, septic or traumatic shock, stroke, and hemorrhage shock.
3o In addition, the patent discusses the utility of these compounds in embryo implantation and in the treatment of cancer, arthritis, and arteriosclerosis. The compounds are not disclosed for ophthalmic use. Some of the tetrahydrosteroids disclosed in Aristoff, et al.
are disclosed in U.S. Patent No. 4,771,042 in combination with heparin or a heparin fragment for inhibiting WO 99/03503 PCT/US98/12'711 angiogenesis in a warm blooded animal. The patent does not disclose the combination for ophthalmic use.
Compositions of hydrocortisone, "tetrahydrocortisol-S," and U-72,7456, each in s combination with a beta cyclodextrin have been shown to inhibit corneal neovascularization.
Li, et al., Angiostatic Steroids Potentiated by Sulphated Cyclodextrin Inhibit Corneal Neovascularization, Investigative Ophthalmology and Visual Science, 32(11):2898-2905, October, 1991. The steroids alone reduce neovascularization somewhat but are not effective alone in providing for regression of neovascularization.
l0 There are currently no effective therapies for the treatment of ocular neovascular diseases which do not include the destruction of healthy viable tissue.
Although panretinal photocoagulation is the current medical practice for the treatment of diabetic retinopathy and is effective in inhibiting diabetic retinal neovascularization, this procedure destroys healthy is peripheral retinal tissue. This destruction of healthy tissue decreases the retinal metabolic demand and thereby reduces retinal ischemia driven neovascularization. A
recent new laser procedure is being tested for the inhibition of ocular neovascularization.
Photodynamic therapy (PDT) is a procedure in which a photoactivatable dye is given systemically followed by laser activation of the dye in the eye at the site of new blood vessel formation (Asrani & Zeimer, Br J
zo Ophthalmol, 79(8):776-770, August, 1995; Asrani et al, Invest Ophthalmol.
Vis Sci, 38(13);2702-2710, December, 1997; Husain et al, Ophthalmology, 104(8):242-1250, August, 1997; Lin et al, Curr Eye Res, 13(7):513-522, 3uly, 1994.) The photoactivated drug generates free oxygen radicals which seal the newly formed blood vessels. This procedure has been used in patients with the exudative form of macular degeneration and many patients show regression zs of their subretinal neovascular membranes. Unfortunately, it appears that the PDT induced inhibition of neovascularization is transient lasting only 6-12 weeks (Gragoudas et al, Investigative Ophthalmology & Visual Science, 38(4):S17; March 15, 1997;
Sickenberg et al, Investigative Ophthalmology & Visual Science, 38(4):S92, March 15, 1997;
Thomas et al, Investigative Ophthalinology & Visual Science, 39(4):S242, March I5, 1998.) t The subject matter of the present invention involves combining the PDT induced regression of ocular neovascular tissue with agents, such as angiostatic steroids, which inhibit new blood vessel formation.
s Summary of the Invention This invention is directed to methods for treating ocular neovascular diseases by combining the use of PDT with particular angiostatic steroids.
Brief Description of the Drawing io Figure 1 - Compares the ability of angiostatic steroids to inhibit neovascularization in the rabbit cornea.
Detailed Description Of The Preferred Embodiments The development of blood vessels for the purpose of sustaining vital tissue is known as is angiogenesis or neovascularization. Agents which inhibit neovascularization are known by a variety of terms such as angiostatic, angiolytic, or angiotropic agents. For purposes of this specification, the term "angiostatic agent" means compounds which can be used to inhibit neovascularization.
zo Ocular neovascularization has not been successfully treated in the past.
Neovascularization of tissues in the front of the eye (i.e. the cornea, iris, and the trabecular meshwork) and other conditions, including conditions in the back of the eye, for example, retinal, subretinal, macular, and optical nerve head neovascularization, can be prevented and treated by administration of the steroids of this invention. The angiostatic agents are useful in zs preventing and treating ocular neovascularization, including providing for the regression of neovascularization.
The angiostatic agents of this invention are steroids available from Steraloids, Inc., Wilton, N.H. and have the following structures and names:

'~Ac O
OH
O O
4,9(11)-Pregnadien-17a,21-diol- 4,9(11)-Pregnadien-17a,21-3,20-dione-21-acetate diol-3,20-dione nH
O O
H OH
O
11-Epicortisol l7alpha-Hydroxyprogesterone off O
~H
HO~~ HO' H
H
Tetrahydrocortexoione (THS) Tetrahydrocortisol (THF) The above structures include all pharmaceutically acceptable salts of the angiostatic steroids.
s The preferred angiostatic steroids are 4,9(11)-pregnadien-17x,21-diol-3,20-dione and 4,9(11}-pregnadien-17a,21-diol-3,20-dione-21-acetate (anecortave acetate).
The angiostatic steroids in combination with PDT are useful in preventing and treating io any ocular neovascularization, including, but not limited to: retinal diseases (diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, age related macular degeneration (ARMD) due to subretinal neovascularization); rubeosis iritis;
inflammatory diseases; chronic uveitis; neoplasms (retinoblastoma, pseudoglioma}; Fuchs' heterochromic iridocyclitis; neovascular glaucoma; corneal neovascularization (inflammatory, transplantation, ~s developmental hypoplasia of the iris}; neovascularization resulting following a combined vitrectomy and lensectomy; vascular diseases (retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, carotid artery ischcmia);
neovascularization of the optic nerve; and neovascularization due to penetration of the eye or contusive ocular injury. In particular, this therapy is useful in the treatment of exudative ARMD and diabetic retinopathy.
zo The initiation of new blood vessel formation may arise quite differently in various tissues or as a result of different diseases. Many substances have been found to induce neovascularization, see, Folkman, et al., Angiogenic Factors, Science, Volume 235, pp. 442-447 (1987). However, it is believed, that once initiated, the process of neovascularization is similar zs in all tissues and regardless of the associated disease, Furcht, Critical Factors Controlling Angiogenesis: Cell Products, Cell Matrix, and Growth Factors, Laboratory Investigation, Volume 55, No. 5, pp. 505-509 (1986).
There are a variety of theories regarding the mechanism of action of angiostatic steroids.
3o For example, angiostatic steroid induced inhibition of neovascularization may occur due to, dissolution of the capillary basement membrane, Ingber, et al., Supra;
inhibition of vascular endothelial cell proliferation, Cariou, et al., Inhibition of Human Endothelial Cell Proliferation by Heparin and Steroids, Cell Biology International Reports, Vol. 12, No. 12, pp. 1037-1047 (December, 1988); effect on vascular endothelial cell laminin expression, Tokida, et al., Production of Two Variant Laminin Forms by Endothelial Cells and Shift of Their Relative s Levels by Angiostatic Steroids, The Journal of Biological Chemistry, Vol.
264, No. 30, pp.
18123-18129 (October 25, 1990); inhibition of vascular cell collagen synthesis, Maragoudakis, et al., Antiangiogenic Action of Heparin Plus Cortisone is Associated with Decreased Collagenous Protein Synthesis in the Chick Chorioallantoic Membrane System, The Journal of Pharmacology and Experimental Therapeutics, Vol. 251, No. 2, pp. 679-682 (I989); and ~o inhibition of vascular endothelial cell plasminogen activator activity, Ashino-Fuse, et al., Medroxyprogesterone Acetate, ,4n Anti-Cancer and Arzti-Angiogenic Steroid, Inhibits the Plasminogen Activator in Bovine Er2dothelial Cells, lnt. J. Cancer, 44, pp.
859-864 (1989).
There are many theories associated with the cause of neovascularization, and there may ~s be different inducers depending on the disease or surgery involved, BenEzra, Neovasculogenic Ability of Prostaglandins, Growth Factor:r, and Svrzthetic Chemoattractants, American Journal of Ophthalmology, Volume 86, No. 4, pp. 455-461, (October, 1978). Regardless of the cause or the associated disease or surgery, it is believed that angiostatic agents work by inhibiting one or more steps in the process of neovascularization. Therefore, the angiostatic steroids of this zo invention are useful in the treatment and prevention of neovascularization associated with a variety of diseases and surgical complications.
The angiostatic steroids of the present invention may be incorporated in various formulations for delivery to the eye. For example, topical formulations can be used and can zs include ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, buffers, sodium chloride, and water to form aqueous sterile ophthalmic solutions and suspensions. In order to prepare sterile ophthalmic ointment formulations, an angiostatic steroid is combined with a preservative in an appropriate vehicle, such as mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations comprising the angiostatic steroids of the 3o present invention can be prepared by suspending an angiostatic steroid in a hydrophilic base prepared from a combination of, for example, Carbopol (a carboxy vinyl polymer available t the BF Goodrich Company) according to published formulations for analogous ophthalmic preparations. Preservatives and antimicrobial agents may also be incorporated in such gel formulations. Ocular injection (intravitreal, subtenons, subconjunctival, periocular, retrobulbar) as well as intraocular slow release devices and implants may be used, particularly for delivery to the back of the eye. Systemic formulations, for example, orally ingested tablets and formulations for intraocular injection are also contemplated.
The specific type of formulation selected will depend on various factors, such as the angiostatic steroid or its salt being used, the dosage frequency, and the location of the io neovascularization being treated. Topical ophthalmic aqueous solutions, suspensions, ointments, and gels are the preferred dosage forms for the treatment of neovascularization in the front of the eye (the cornea, iris, trabecular meshwork); or neovascularization of the back of the eye if the angiostatic agent can be formulated such that it can be delivered topically and the agent is able to penetrate the tissues in the front of the eye. The angiostatic steroid will ~ s normally be contained in these and other formulations in an amount from about 0.01 to about 1 S.0 weightlpercent. Preferable concentrations range from about 0.1 to about 7.5 weight/percent. Thus, for topical administration, these formulations are delivered to the surface of the eye one to six times a day, depending on the routine discretion of the skilled clinician.
Systemic administration, for example, in the form of tablets is useful for the treatment of zo neovascularization particularly of the back of the eye, for example, the retina. Tablets containing 10-100 mg of angiostatic agent can be taken 2-3 times per day depending on the discretion of the skilled clinician.
The compounds, no matter how delivered, can be administered prior to, during, and/or zs after PDT. It is preferred to administer the compounds both before and after surgury to slow or prevent the reoccurrence of neovascularization.
The following examples illustrate formulations of the present invention, but are in no way limiting.

Example 1 Topical Ocular Formulation Ingredient Amount (wt.%) Anecortave Acetate 1.0 Tyloxapol 0.01 to 0.05 i o HPMC 0.5 Benzalkonium Chloride 0.01 Sodium Chloride 0.8 ~s Edetate Disodium 0.01 NaOH/HCl q.s. pH 7.4 zo Purified Water q.s. 100 mL
The formulation is prepared by first placing a portion of the purified water into a beaker and heating to 90°C. The hydroxypropyhnethylcellulose (HPMC) is then added to the heated zs water and mixed by means of vigorous vortex stirring until all of the HPMC
is dispersed. The resulting mixture is then allowed to cool while undergoing mixing in order to hydrate the HPMC. The resulting solution is then sterilized by means of autoclaving in a vessel having a liquid inlet and a hydrophobic, sterile air vent filter.
3o The sodium chloride and the edetate disodium are then added to a second portion of the purified water and dissolved. The benzalkonium chloride is then added to the solution, and the pH of the solution is adjusted to 7.4 with O.1M NaOH/HCI. The solution is then sterilized by means of filtration.
3s The 4,9(lI)-Pregnadien-17a,21-diol-3,20-dione-21-acetate is sterilized by either dry heat or ethylene oxide. If ethylene oxide sterilization is selected, aeration for at least 72 hours at 50°C is necessary. The sterilized 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate is r weighed aseptically and placed into a pressurized ballmill container. The tyloxapol, in sterilized aqueous solution form, is then added to the ballmill container. Sterilized glass balls are then added to the container and the contents of the container are milled aseptically at 225 rpm for 16 hours, or until all particles are in the range of approximately 5 microns.
s Under aseptic conditions, the micronized drug suspension formed by means of the preceding step is then poured into the HPMC solution with mixing. The balhnill container and balls contained therein are then rinsed with a portion of the solution containing the sodium chloride, the edetate disodium and benzalkonium chloride. The rinse is then added aseptically io to the HPMC solution. The final volume of the solution is then adjusted with purified water and, if necessary, the pH of the solution is adjusted to pH 7.4 with NaOH/HCI.
The formulation will be given topically, in a therapeutically effective amount. In this instance, the phrase "therapeutically effective amount" means an amount which is sufficient to substantially prevent or reverse any ocular neovascularization. The dosage regimen used will depend on the nature of i s the neovascularization, as well as various other factors such as the patient's age, sex, weight, and medical history.
Example 2 Topical Ocular Formulation zo Ingredient Amount (wt.%) Anecortave Acetate 1.0 zs Mannitol 2.40 Sodium Chloride 0.40 Carbopol 974P 0.50 Polysorbate 80 0.05 Edetate Disodium 0.01 3s Benzalkonium Chloride 0.01 + 5% XS
Sodium Hydroxide adjust pH to 7.2 Purified Water qs to 100%

Example 3 Tablet:
s 5-100 mg anecortave acetate with inactive ingredients such as starch, lactose and magnesium stearate can be formulated according to procedures known to those skilled in the art of tablet formulation.
Example 4 ~o Formulation for Sterile Intraocular Injection each mL contains:
4,9(11)-Pregnadien-17a,21-diol-3,20-dione 10-100 mg ~s Sodium Chloride 7.14 mg Potassium Chloride 0.38 mg Calcium chloride dihydrate 0.154 mg Magnesium chloride hexahydrate 0.2 mg Dried sodium phosphate 0.42 mg Zo Sodium bicarbonate 2.1 mg Dextrose 0.92 mg Hydrochloric acid or sodium hydroxide to adjust pH to approximately 7.2 Water for injection Example 5 Sterile Injection Formulation List of Components m ml s Anecortave Acetate 0.1-150 (0.0 for vehicle) Monobasic Sodium Phosphate, Monohydrate 0.1-5 Diabasic Sodium Phosphate, Anhydrous 0.1-5 ~o Tyloxapol 0.0-10 Sodium Chloride 0.1-10 is Hydrochloric Acid and/or Sodium Hydroxide Adjust pH 7.0 - 7.8 Water for Injection q,s, zo Example 6 Sterile Injection Formulation List of Compounds m~/ml 2s Anecortave Acetate 60 Monobasic Sodium Phosphate, Monohydrate 0.45 Dibasic Sodium Phosphate, Anhydrous 2.0 Tyloxapol 4.0 Sodium Chloride ~.p 3s Hydrochloric Acid and/or Sodium Hydroxide Adjust pH 7.4 t 0.2 Water for Injection q,s WO 99!03503 PCT/US98/12711 Example 7 Inhibition of angiogenesis in the rabbit corneal neovascularization model:
s The corneal pocket system of BenEzra (Am. J. Ophthalmol 86:455-461, 1978) was used to induce corneal neovascularization in the rabbit. A small Elvax pellet containing O.S~g of lipopolysaccharide (LPS) was inserted into the middle of the corneal stroma and positioned 2.5 mm from the limbus. An additional to Elvax pellet with or without SOUg of angiostatic steroid was placed next to the LPS implant. The eyes were examined daily and the area of neovascularization calculated. Results after 8 days of LPS implantation are shown in Figure 1.
THF - tetrahydrocortisol; A = 4,9(11)-Pregnadien-17a,21-diol-3,20-dione-21-acetate; B = 4,9(11)-Pregnadien-17a,21-diol-3,20-dione. As can be seen, A & B
s totally inhibited corneal neovascularization, whereas THF partially inhibited the neovascular response.

t

Claims (5)

I Claim:
1. A method for preventing and treating ocular neovascularization, which comprises the use of PDT in combination with a compound selected from the group consisting of:
4,9(11)-Pregnadien-17.alpha.,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17.alpha.,21-diol-3,20-dione, 11-Epicortisol, l7alpha-Hydroxyprogesterone, Tetrahydrocortexolone (THS), and Tetrahydrocortisol (THF).
2. The method of Claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17.alpha.,21-diol-3,20-dione-21-acetate.
3. The method of Claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17.alpha.,21-diol-3,20-dione.
4. The method of Claim 1 wherein the angiostatic steroid is administered at a concentration of about 0.01 to 15.0 weight percent.
5. The method of Claim 4 wherein the angiostatic steroid is administered at a concentration of about 0.1 - 7.5 weight percent.
CA002296558A 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy of ocular neovascularization Abandoned CA2296558A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/895,184 US5770592A (en) 1991-11-22 1997-07-16 Prevention and treatment of ocular neovascularization using angiostatic steroids
US08/895,184 1997-07-16
PCT/US1998/012711 WO1999003503A1 (en) 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy

Publications (1)

Publication Number Publication Date
CA2296558A1 true CA2296558A1 (en) 1999-01-28

Family

ID=25404127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002296558A Abandoned CA2296558A1 (en) 1997-07-16 1998-06-18 The use of angiostatic steroids in photodynamic therapy of ocular neovascularization

Country Status (13)

Country Link
US (2) US5770592A (en)
EP (1) EP1003553B1 (en)
JP (1) JP2001510170A (en)
AT (1) ATE274356T1 (en)
AU (1) AU734195B2 (en)
BR (1) BR9811012A (en)
CA (1) CA2296558A1 (en)
DE (1) DE69825906T2 (en)
DK (1) DK1003553T3 (en)
ES (1) ES2224412T3 (en)
HK (1) HK1028952A1 (en)
PT (1) PT1003553E (en)
WO (1) WO1999003503A1 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1154691A4 (en) * 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Targeted transscleral controlled release drug delivery to the retina and choroid
JP2002534218A (en) 1999-01-15 2002-10-15 ライト サイエンシーズ コーポレイション Non-invasive vascular therapy
ATE234114T1 (en) * 1999-01-15 2003-03-15 Light Sciences Corp THERAPEUTIC COMPOSITIONS FOR BONE METABOLIC DISORDERS OR BONE METASTASIS CONTAINING A PHOTOSENSITIZER AND A BISPHOSPHONATE
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
PT1221918E (en) 1999-10-21 2005-06-30 Alcon Inc ADMINISTRATION OF SUB-TENON DRUGS
CN1292721C (en) * 1999-10-21 2007-01-03 爱尔康公司 Drug delivery device
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
AU3497901A (en) * 2000-02-10 2001-08-20 Massachusetts Eye & Ear Infirm Methods and compositions for treating conditions of the eye
AR032151A1 (en) * 2000-03-24 2003-10-29 Novartis Ag USE OF AN ANTI-ANGIOGENIC PHARMACO IN CONJUNCTION WITH A PHOTOSENSIBLE AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE IMPROVED PHOTODYNAMIC TREATMENT OF INDOVATED NEOVASCULATURE
EP1570859A3 (en) * 2000-03-24 2008-04-02 Novartis AG Improved treatment of neovascularization
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US9820883B2 (en) * 2000-05-19 2017-11-21 Michael S. Berlin Method for treating glaucoma
US8679089B2 (en) 2001-05-21 2014-03-25 Michael S. Berlin Glaucoma surgery methods and systems
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
CN1203814C (en) 2001-07-23 2005-06-01 爱尔康公司 Opthalmic drug delivery device
WO2003009784A1 (en) * 2001-07-23 2003-02-06 Alcon, Inc. Ophthalmic drug delivery device
CA2462456C (en) * 2001-10-03 2010-05-04 Merck & Co., Inc. Androstane 17-beta-carboxamides as androgen receptor modulators
EP1441743A4 (en) * 2001-11-09 2009-02-25 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US7847101B2 (en) 2002-07-24 2010-12-07 Valocor Therapeutics, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
US6828356B2 (en) * 2002-07-29 2004-12-07 Ast Products, Inc. Preparation of ophthalmic compositions
US6806364B2 (en) * 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
CA2494449A1 (en) * 2002-07-29 2004-02-05 Ast Products, Inc. Ophtalmic compositions
RU2322239C2 (en) * 2002-08-05 2008-04-20 Алькон, Инк. Method for applying anecortavi acetas for protecting patient vision acuity having age-specific yellow spot degeneration
DE10238310A1 (en) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh electrode assembly
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US20040167109A1 (en) * 2003-02-20 2004-08-26 Bingaman David P Formulations of glucocorticoids to treat pathologic ocular angiogenesis
PL378210A1 (en) * 2003-02-20 2006-03-20 Alcon, Inc. Use of steroids to treat ocular disorders
KR20060019579A (en) * 2003-06-13 2006-03-03 알콘, 인코퍼레이티드 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
WO2004112796A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
CA2522592A1 (en) * 2003-07-10 2005-02-03 Alcon, Inc. Ophthalmic drug delivery device
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
KR20060095974A (en) * 2003-09-23 2006-09-05 알콘, 인코퍼레이티드 Triamcinolone acetonide and anecortave acetate formulations for injection
WO2005072744A1 (en) * 2004-02-02 2005-08-11 Yuichi Kaji Vitreous-visualizing agents
CN1980929A (en) * 2004-02-24 2007-06-13 比奥阿克松医疗技术股份有限公司 4-substituted piperidine derivatives
US20050239760A1 (en) * 2004-04-23 2005-10-27 Alcon, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
CA2581126A1 (en) 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
AU2006250914B2 (en) 2005-05-25 2012-03-01 Chemisches Institut Schaefer Ag Biocompatible polymers and co-polymers comprising amino acids in the side chain
EP2446887A3 (en) * 2005-07-12 2012-08-15 DMI Biosciences, Inc. Use of danazol for the treatment of Alzheimer's disease
BRPI0615962A2 (en) 2005-07-27 2011-05-31 Univ Florida use of a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lysosomal inhibitor, an golgi er protein transport inhibitor, an hsp90 chaperonin inhibitor, a heat shock response activator, a and a histone deacetylase inhibitor, use of 11-cis-retinal or 9-cis-retinal and a compound selected from the group consisting of a proteasome inhibitor, an autophagy inhibitor, a lissosomal inhibitor, a er to golgi protein, a hsp90 chaperonin inhibitor, a heat shock response activator, a glycosidase inhibitor, and a histone deacetylase inhibitor, a method for increasing the amount of a biochemically functional conformation of a protein in a cell, composition pharmaceutical for the treatment of an ocular pcd, pharmaceutical composition for the treatment of retinitis pigmentosa, kit for the treatment of an ocular pcd, kit for the treatment retinitis pigmentosa, method for identifying a compound useful for the treatment of an individual having an ocular pcd, method for identifying a compound useful for the treatment of an individual having retinitis pigmentosa, use of a proteasome inhibitor or a autophagy inhibitor and method for producing a recombinant protein in a biochemically functional conformation
HUE025608T2 (en) * 2005-09-07 2016-03-29 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2007047744A2 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
US20080125406A1 (en) * 2005-10-14 2008-05-29 Robin Alan L Method for Treating Primary and Secondary Forms of Glaucoma
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
EA016227B1 (en) 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Method of treating ocular neovascular disorders
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
CN101443004B (en) 2006-03-23 2013-03-06 参天制药株式会社 Formulations and methods for vascular permeability-related diseases or conditions
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US20090181933A1 (en) * 2008-01-11 2009-07-16 Bingaman David P Use of steroids to treat persons suffering from ocular disorders
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
DK2805720T3 (en) 2008-05-28 2019-09-02 Reveragen Biopharma Inc Non-hormonal steroid modulators of NF-κB for the treatment of disease
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
IN2012DN00352A (en) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
PL2554171T3 (en) 2009-06-22 2015-03-31 Ampio Pharmaceuticals Inc Method for treatment of diseases
CA2766192C (en) 2009-07-09 2017-10-24 Ivantis, Inc. Ocular implants for residing partially in schlemm's canal
US9693899B2 (en) 2009-07-09 2017-07-04 Ivantis, Inc. Single operator device for delivering an ocular implant
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
US20120283557A1 (en) 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US9133082B2 (en) 2011-06-14 2015-09-15 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9499464B2 (en) 2011-10-19 2016-11-22 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2785346A4 (en) 2011-11-30 2015-04-29 Bikam Pharmaceuticals Inc Opsin-binding ligands, compositions and methods of use
AU2012346537A1 (en) 2011-12-01 2014-07-17 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
US11197779B2 (en) 2015-08-14 2021-12-14 Ivantis, Inc. Ocular implant with pressure sensor and delivery system
WO2017106517A1 (en) 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
WO2019014322A1 (en) 2017-07-11 2019-01-17 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
EP4274529A1 (en) 2021-01-11 2023-11-15 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
DE69132048T2 (en) * 1990-06-11 2000-07-13 Alcon Lab Inc N D Ges D Staate Use of steroids to inhibit angiogenesis
WO1995024930A1 (en) 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy

Also Published As

Publication number Publication date
EP1003553A1 (en) 2000-05-31
AU8151598A (en) 1999-02-10
WO1999003503A1 (en) 1999-01-28
JP2001510170A (en) 2001-07-31
ES2224412T3 (en) 2005-03-01
HK1028952A1 (en) 2001-03-16
ATE274356T1 (en) 2004-09-15
US5770592A (en) 1998-06-23
BR9811012A (en) 2000-10-17
PT1003553E (en) 2004-10-29
AU734195B2 (en) 2001-06-07
DE69825906T2 (en) 2005-09-01
DK1003553T3 (en) 2004-09-20
DE69825906D1 (en) 2004-09-30
EP1003553B1 (en) 2004-08-25
US6297228B1 (en) 2001-10-02

Similar Documents

Publication Publication Date Title
EP1003553B1 (en) The use of angiostatic steroids in photodynamic therapy
US5679666A (en) Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
EP0614463B1 (en) Angiostatic steroids
US6011023A (en) Angiostatic steroids
JPH0725679B2 (en) Intraocular pressure control agent
JP2007056041A (en) Glucocorticoid prescription for treating neovascularization in morbid eye
US20060211662A1 (en) Combination therapy for topical application in the treatment of age-related macular degeneration and ocular hypertension
US5929111A (en) A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
MXPA99011140A (en) The use of angiostatic steroids in photodynamic therapy
US20080234245A1 (en) Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma
WO1997041867A1 (en) Use of steroid compounds to prevent non-cancerous tissue growth
AU2004249167A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
CN1239161C (en) Method for treating dry eye disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued